The Haemophilia Society welcomes the Government’s announcement of a public inquiry into the contaminated blood scandal. Our members and campaigners will be pleased and relieved that after decades of campaigning there will finally be an inquiry into how over 5,000 people with bleeding disorders were infected by contaminated blood products.
Tagged as: hepatitis C
Party Leaders Demand Inquiry into Contaminated Blood Scandal
The leaders of the political parties represented in the House of Commons have written to the Prime Minister to demand an inquiry into the contaminated blood scandal. The letter calls for a Hillsborough-style inquiry and says that “concerning allegations about what officials knew at the time, and when, have been
Legal Action adds to Pressure for Public Inquiry into Contaminated Blood Products
The Haemophilia Society’s campaign for a public inquiry into the scandal of contaminated blood products got a boost today as legal action was launched in the High Court. Papers were lodged for a group legal action on grounds of negligence/breach of duty against the Government. Welcoming the development, Liz Carroll
MPs call for an Inquiry into the Contaminated Blood Scandal
A debate was held this afternoon in Parliament on Contaminated Blood led by Andy Burnham. Many other MPs from across the house rose to speak in support of those affected by contaminated blood products. Mr Burnham provided evidence of medical records that were changed or contained false information, diagnosis of
APPG on Haemophilia and Contaminated Blood – Latest Meeting
The APPG on Haemophilia and Contaminated Blood met on the 29th March. The Agenda for the Meeting was: Introductions and Apologies New Contaminated Blood Support consultation Aspects of the new proposals The new scheme administrator Plans for engagement Proposed meeting with Lord O’Shaughnessy Update on actions from the last meeting
Response to the Contaminated Blood Announcement and Consultation
Overview The Department of Health (DH) today published a written ministerial statement announcing some changes to the support scheme for people affected by contaminated blood and launching a new consultation on the Special Category Mechanism and the discretionary support scheme. The consultation will run for six weeks, until the 17th
Direct-acting Antiviral (DAA) treatment for Hepatitis C risks Hepatitis B reactivation
New guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) advises that all hepatitis C patients should be screened for hepatitis B before starting treatment with new Direct-acting Antivirals (DAAs). If patients are infected with both viruses this does not preclude treatment but this should be monitored and managed.
12